What is Leerink Partnrs' Forecast for MLTX Q2 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a report released on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.82) for the quarter. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics' Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2029 earnings at $7.54 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09).

Other equities analysts also recently issued reports about the company. Wedbush reiterated an "outperform" rating and issued a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. The Goldman Sachs Group dropped their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Needham & Company LLC boosted their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of "Buy" and an average price target of $83.20.

Remove Ads

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ MLTX traded up $0.59 during mid-day trading on Friday, hitting $40.30. 224,767 shares of the stock traded hands, compared to its average volume of 343,255. The company has a market cap of $2.58 billion, a PE ratio of -31.24 and a beta of 1.28. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $58.26. The firm has a 50 day simple moving average of $46.24 and a two-hundred day simple moving average of $48.89.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MLTX. FMR LLC lifted its stake in MoonLake Immunotherapeutics by 28.1% in the fourth quarter. FMR LLC now owns 6,341,391 shares of the company's stock valued at $343,386,000 after buying an additional 1,391,167 shares during the period. Paradigm Biocapital Advisors LP lifted its position in shares of MoonLake Immunotherapeutics by 90.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock valued at $95,965,000 after acquiring an additional 840,731 shares during the period. Polar Capital Holdings Plc boosted its stake in MoonLake Immunotherapeutics by 120.0% during the fourth quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company's stock worth $59,565,000 after acquiring an additional 600,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock worth $181,059,000 after purchasing an additional 363,394 shares during the period. Finally, Federated Hermes Inc. increased its stake in MoonLake Immunotherapeutics by 13.2% in the fourth quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock valued at $69,315,000 after purchasing an additional 149,724 shares in the last quarter. 93.85% of the stock is owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.